Bruton's tyrosine kinase inhibitors in diffuse large B-cell lymphoma therapy: critical considerations and future innovations.
0/5 보강
APA
Lu C, Chen Q, et al. (2026). Bruton's tyrosine kinase inhibitors in diffuse large B-cell lymphoma therapy: critical considerations and future innovations.. Journal of translational medicine, 24(1). https://doi.org/10.1186/s12967-026-07798-8
MLA
Lu C, et al.. "Bruton's tyrosine kinase inhibitors in diffuse large B-cell lymphoma therapy: critical considerations and future innovations.." Journal of translational medicine, vol. 24, no. 1, 2026.
PMID
41872926 ↗
같은 제1저자의 인용 많은 논문 (5)
- The ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseases.
- Immunosensors for dual tumor biomarker detection based on ternary electrochemiluminescence using confined CeO nanozyme as Co-reactant enhancers for luminol-O system.
- Opportunities and challenges of targeting cGAS-STING in cancer.
- zDHHC-mediated palmitoylation modification patterns and tumor immune microenvironment infiltration characterization in pancreatic cancer.
- Correlations between iodine status and the risk of thyroid nodules, a systematic review and dose-response meta-analysis.